Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
- Jan 07, 2021 (filed on Jan 13, 2021)Insider Name:Thornton BruceOwnership Type:Direct OwnershipSecurities:Stock option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:27,777Price:--
- Jan 07, 2021 (filed on Jan 08, 2021)Insider Name:Dvonch Jerome JOwnership Type:Direct OwnershipSecurities:Stock option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:27,777Price:--
- Jan 07, 2021 (filed on Jan 08, 2021)Insider Name:Trombly Amy MossOwnership Type:Direct OwnershipSecurities:Stock option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:27,777Price:--
- Apr 23, 2020 (filed on Apr 24, 2020)Insider Name:Edwards Robert GrantOwnership Type:Direct OwnershipSecurities:Common Stock, $0.0001 par valueNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:2,609Price:--
- Apr 23, 2020 (filed on Apr 24, 2020)Insider Name:Dal Poggetto JohnOwnership Type:Direct OwnershipSecurities:Common Stock, $0.0001 par valueNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:3,086Price:--
Filings by filing date
- Jan 07, 2021 (filed on Jan 13, 2021)Insider Name:Thornton BruceOwnership Type:Direct OwnershipSecurities:Stock option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:27,777Price:--
- Jan 07, 2021 (filed on Jan 08, 2021)Insider Name:Dvonch Jerome JOwnership Type:Direct OwnershipSecurities:Stock option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:27,777Price:--
- Jan 07, 2021 (filed on Jan 08, 2021)Insider Name:Trombly Amy MossOwnership Type:Direct OwnershipSecurities:Stock option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:27,777Price:--
- Apr 23, 2020 (filed on Apr 24, 2020)Insider Name:Edwards Robert GrantOwnership Type:Direct OwnershipSecurities:Common Stock, $0.0001 par valueNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:2,609Price:--
- Apr 23, 2020 (filed on Apr 24, 2020)Insider Name:Dal Poggetto JohnOwnership Type:Direct OwnershipSecurities:Common Stock, $0.0001 par valueNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:3,086Price:--
News
Biz Brief
| Sector: Healthcare | Industry: Pharmaceuticals |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 645 Molly Lane, Suite 150 WOODSTOCK GA 30189 |
| Tel: | N/A |
| Website: | https://sonomapharma.com |
| IR: | See website |
| Key People | ||
| Amy Trombly Chief Executive Officer | Jerry Dvonch Chief Financial Officer | Bruce Thornton Chief Operating Officer, Secretary |
| Business Overview |
| Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and markets solutions for management of dermatological conditions and advanced tissue care. The Company's product portfolio consists of dermatology, animal health, and advanced tissue care products based upon its Microcyn technology. Its Microcyn technology family of products consists of liquids and gels, which contain small molecule oxychlorine compounds. Its products serve patients across the globe by reducing infections, itch, pain, scarring and inflammatory responses. Its products are sold throughout the United States and internationally. |
| Financial Overview |
| For the six months ended 30 September 2020, SonomaPharmaceuticals Inc revenues increased 25% to $11.5M. Netloss before extraordinary items decreased 9% to $557K.Revenues reflect Human Skin Care segment increase of 17% to$7.4M, Animal Skin Care segment increase of 75% to $2.4M,Latin America segment increase from $1.7M to $4.4M, Europeand Rest of the World segment increase of 27% to $3.6M. |
| Employees: | 18 as of Mar 31, 2020 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $14.54M as of Sep 30, 2020 |
| Annual revenue (TTM): | $20.79M as of Sep 30, 2020 |
| EBITDA (TTM): | -$3.96M as of Sep 30, 2020 |
| Net annual income (TTM): | -$3.02M as of Sep 30, 2020 |
| Free cash flow (TTM): | -$7.31M as of Sep 30, 2020 |
| Net Debt Last Fiscal Year: | N/A |
| Shares outstanding: | 2,075,447 as of Dec 22, 2020 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |